60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. LaunchGlobeNewsWire • 10/03/24
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 09/04/24
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing RequirementsGlobeNewsWire • 08/28/24
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/14/24
60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb StudyGlobeNewsWire • 08/12/24
60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade SupportGlobeNewsWire • 07/25/24
60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis StudyGlobeNewsWire • 07/19/24
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior TreatmentGlobeNewsWire • 07/09/24
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its KindGlobeNewsWire • 06/27/24
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its KindGlobeNewsWire • 05/30/24
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine StudyGlobeNewsWire • 05/20/24
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesGlobeNewsWire • 05/08/24
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes RequiredGlobeNewsWire • 05/02/24
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisGlobeNewsWire • 04/03/24
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024GlobeNewsWire • 03/14/24
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisGlobeNewsWire • 02/20/24
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial OfficerGlobeNewsWire • 02/08/24
WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingPRNewsWire • 01/31/24